Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Vaxcyte (PCVX) Enterprise Value (2020 - 2026)

Vaxcyte (PCVX) has 8 years of Enterprise Value data on record, last reported at -$1.7 billion in Q1 2026.

  • On a quarterly basis, Enterprise Value fell 3.91% to -$1.7 billion in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.7 billion, a 3.91% decrease, with the full-year FY2025 number at -$1.6 billion, up 10.66% from a year prior.
  • Enterprise Value reached -$1.7 billion in Q1 2026 per PCVX's latest filing, down from -$1.6 billion in the prior quarter.
  • Over the last five years, Enterprise Value for PCVX hit a ceiling of -$334.6 million in Q1 2022 and a floor of -$2.2 billion in Q3 2024.
  • A 5-year average of -$1.3 billion and a median of -$1.5 billion in 2024 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: plummeted 278.65% in 2022, then increased 21.52% in 2025.
  • Tracing PCVX's Enterprise Value over 5 years: stood at -$931.4 million in 2022, then decreased by 15.98% to -$1.1 billion in 2023, then crashed by 61.74% to -$1.7 billion in 2024, then grew by 10.66% to -$1.6 billion in 2025, then fell by 11.29% to -$1.7 billion in 2026.
  • Business Quant data shows Enterprise Value for PCVX at -$1.7 billion in Q1 2026, -$1.6 billion in Q4 2025, and -$1.7 billion in Q3 2025.